Hayden Royal’s Utah Medical Products UTMD Stock Holding History

Hayden Royal’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,709	Closed	-$661K	–	232
2020 Q2	$661K	Buy	+11,709	New	+$1.05M	0.37%	62

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Hayden Royal's UTMD Position: Q3 2020 in Review

Hayden Royal sold out of Utah Medical Products (UTMD) in Q3 2020, closing a stake of 11,709 shares — an estimated $661K sold.

Hayden Royal first reported a position in UTMD in Q2 2020 and held it in 1 quarter. The position peaked at $661K in Q2 2020. 85 funds tracked by Wall St. Rank hold UTMD as of Q3 2020.

Hayden Royal reported no remaining Utah Medical Products position as of Q3 2020 after selling out during the quarter.
Hayden Royal sold 11,709 Utah Medical Products shares in Q3 2020, an estimated $661K.
Hayden Royal first reported a position in Utah Medical Products in Q2 2020 and held it in 1 quarter.
Hayden Royal's Utah Medical Products position peaked at $661K in Q2 2020.
85 funds tracked by Wall St. Rank held Utah Medical Products as of Q3 2020.

Based on Hayden Royal's 13F filing for Q3 2020, filed 6 Nov 2020.